1. Home
  2. DRCT vs RNXT Comparison

DRCT vs RNXT Comparison

Compare DRCT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRCT
  • RNXT
  • Stock Information
  • Founded
  • DRCT 2018
  • RNXT 2012
  • Country
  • DRCT United States
  • RNXT United States
  • Employees
  • DRCT N/A
  • RNXT N/A
  • Industry
  • DRCT Computer Software: Programming Data Processing
  • RNXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • DRCT Technology
  • RNXT Health Care
  • Exchange
  • DRCT Nasdaq
  • RNXT Nasdaq
  • Market Cap
  • DRCT 38.7M
  • RNXT 33.8M
  • IPO Year
  • DRCT 2022
  • RNXT 2021
  • Fundamental
  • Price
  • DRCT $1.29
  • RNXT $1.50
  • Analyst Decision
  • DRCT Strong Buy
  • RNXT Strong Buy
  • Analyst Count
  • DRCT 3
  • RNXT 2
  • Target Price
  • DRCT $21.00
  • RNXT $6.50
  • AVG Volume (30 Days)
  • DRCT 7.7M
  • RNXT 101.2K
  • Earning Date
  • DRCT 11-12-2024
  • RNXT 11-13-2024
  • Dividend Yield
  • DRCT N/A
  • RNXT N/A
  • EPS Growth
  • DRCT N/A
  • RNXT N/A
  • EPS
  • DRCT N/A
  • RNXT N/A
  • Revenue
  • DRCT $94,216,000.00
  • RNXT N/A
  • Revenue This Year
  • DRCT N/A
  • RNXT N/A
  • Revenue Next Year
  • DRCT $37.23
  • RNXT N/A
  • P/E Ratio
  • DRCT N/A
  • RNXT N/A
  • Revenue Growth
  • DRCT N/A
  • RNXT N/A
  • 52 Week Low
  • DRCT $0.51
  • RNXT $0.77
  • 52 Week High
  • DRCT $35.88
  • RNXT $1.86
  • Technical
  • Relative Strength Index (RSI)
  • DRCT 46.10
  • RNXT 64.78
  • Support Level
  • DRCT $1.10
  • RNXT $1.26
  • Resistance Level
  • DRCT $2.61
  • RNXT $1.60
  • Average True Range (ATR)
  • DRCT 0.50
  • RNXT 0.12
  • MACD
  • DRCT -0.07
  • RNXT 0.01
  • Stochastic Oscillator
  • DRCT 8.64
  • RNXT 72.22

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: